Therapeutic Advances in Psychopharmacology
September 1, 2025
Sally Meikle, Olivia Carter, Paul Liknaitzky et al.
2 citations
Background: Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments. Novel psychedelic therapies show promise but require further research. Objectives: This study aimed to evaluate the feasibility, safety and effectiveness of psilocybin with psychotherapeutic support for treatment-resistant depression (TRD), investigate predictors of...
Translational Psychiatry
August 29, 2025
Anton L. V. Avanceña, Linh N. Vuong, James G. Kahn et al.
8 citations
Abstract Psilocybin-assisted therapy (PAT) has been shown in early trials to reduce the symptoms of treatment-resistant depression (TRD). This study evaluated the cost-effectiveness of PAT as a third-line treatment for major depressive disorder compared to standard of care (SOC). We used an individual-level, probabilistic simulation model that portrays representative US adults with TRD who...
The International Journal of Psychiatry in Medicine
August 20, 2025
Harold G. Koenig
of
medRxiv
August 16, 2025
S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey et al.
preprint
Abstract Importance Depression is a major cause of disability worldwide, motivating substantial interest in psilocybin as a potential treatment. Objective To conduct a systematic review and meta-analysis of psilocybin’s impact on depressive symptoms and provide a living open data resource. Data Sources PubMed, Embase, Scopus, Web of Science, and PsycINFO retrieved by a systematic search up to...
General Hospital Psychiatry
August 12, 2025
Margaret Ross, Ravi Iyer, M.l. Williams et al.
13 citations
Psilocybin-assisted psychotherapy appears safe and may offer durable relief from depression and anxiety in individuals with a life-threatening illness.
Exploration of Neuroscience
August 7, 2025
Trevor R. Norman
2 citations
Treatment resistant depression (TRD) is frequently encountered in clinical practice. The lack of response of the condition to conventional medications and augmentation strategies has spawned the search for novel treatment approaches. Psychedelic medications used in conjunction with intensive psychotherapy, so-called psychedelic-assisted psychotherapy (PAP), have been evaluated in a limited...
Frontiers in Psychiatry
August 4, 2025
Wierzbicka Małgorzata, Renata Kopczyk, Alexander L. Gerlach et al.
1 citation
Depression prevalence is markedly elevated in oncological patients, particularly among head and neck cancer (HNC) cohorts, who face twice the prevalence of major depressive disorder (MDD) compared to other cancer populations. MDD in this context independently predicts poorer clinical outcomes and increased morbidity. HNC management often involves acute surgical interventions with disfiguring...
Cureus
August 1, 2025
Brett Hughes, Soz Mirza, Manasi Ponamala et al.
The stresses of the Coronavirus Disease of 2019 (COVID-19) pandemic highlighted the burden of psychiatric disorders within the pediatric population, revealing a pre-existing need for rapid-onset therapies that have since driven efforts to expand effective therapeutic interventions. In this narrative review, we utilized the Preferred Reporting Items for Systematic reviews and Meta-Analysis...
The International Journal of Neuropsychopharmacology
August 1, 2025
Giovanni Martinotti, Clara Cavallotto, Giacomo D’andrea et al.
Abstract Background Among the innovative treatments investigated for depression, psilocybin appears to play an extremely promising role, with several studies showing remission rates up to 70% in patients with treatment-resistant depression (TRD) treated with protocols involving a single or double dose administration [1,2]. Psilocybin is a psychedelic compound belonging to the tryptamine class,...
The International Journal of Neuropsychopharmacology
August 1, 2025
Susan Meikle, Olivia Carter, Paul Liknaitzky et al.
Abstract Background Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments or left with residual symptoms such as impairments in cognition and social functioning. Emerging psychedelic therapies show promise for treating depression but require further research. Aims & Objectives This pilot study aimed to evaluate the feasibility,...